This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Chloroplasts have their own ribosomes, which they use to synthesize a small fraction of their proteins. Chloroplast ribosomes are about two-thirds the size of cytoplasmic ribosomes (around 17 nm vs 25 nm). They take mRNAs transcribed from the chloroplast DNA and translate them into protein. While similar to bacterial ribosomes, chloroplast translation is more complex than in bacteria, so chloroplast ribosomes include some chloroplast-unique features. Small subunit ribosomal RNAs in several Chlorophyta and euglenid chloroplasts lack motifs for Shine-Dalgarno sequence recognition, which is considered essential for translation initiation in most chloroplasts and prokaryotes. Such loss is also rarely observed in other plastids and prokaryotes. An additional 4.5S rRNA with homology to the 3' tail of 23S is found in "higher" plants.
=== Hemorrhagic === Hemorrhagic smallpox is a severe form accompanied by extensive bleeding into the skin, mucous membranes, gastrointestinal tract, and viscera. This form develops in approximately 2% of infections and occurs mostly in adults. Pustules do not typically form in hemorrhagic smallpox. Instead, bleeding occurs under the skin, making it look charred and black, hence this form of the disease is also referred to as variola nigra or "black pox". Hemorrhagic smallpox has very rarely been caused by variola minor virus. While bleeding may occur in mild cases and not affect outcomes, hemorrhagic smallpox is typically fatal. Vaccination does not appear to provide any immunity to either form of hemorrhagic smallpox and some cases even occurred among people that were revaccinated shortly before. It has two forms.
This balance-of-power principle, once formulated, became an axiom of political science. Fénelon, in his Instructions, impressed the axiom upon the young French Dauphin. Frederick the Great, in his Anti-Machiavel, proclaimed the principle to the world. In 1806, Friedrich von Gentz re-stated it with admirable clarity, in Fragments on the Balance of Power. The principle formed the basis of the coalitions against Louis XIV and Napoleon, and the occasion (or excuse) for most of the European wars between the Peace of Westphalia (1648) and the Congress of Vienna (1814). It was especially championed by Great Britain, even up to World War I, as it sought to prevent a European land power from rivaling its naval supremacy. During the greater part of the 19th century, the series of national upheavals which remodeled the map of Europe obscured the balance of power. Yet, it underlaid all the efforts of diplomacy to tame the forces of nationalism let loose by the French Revolution. In the revolution's aftermath, with the restoration of comparative calm, the principle once more emerged as the operative motive for the various political alliances, of which the ostensible object was the preservation of peace. Regarding the era 1848–1914, English diplomatic historian A.J.P. Taylor argued:
On 17 October 1971, Gajowniczek was a special guest of Pope Paul VI in the Vatican when Maximilian Kolbe was beatified for his martyrdom. In 1972, Time magazine reported that over 150,000 people made a pilgrimage to Auschwitz to honor the anniversary of Kolbe's beatification. One of the first to speak was Gajowniczek, who declared "I want to express my thanks for the gift of life." His wife, Helena, died in 1977. Gajowniczek was in the Vatican once again, this time as a guest of Pope John Paul II, when Kolbe was canonized on 10 October 1982. In 1994, Gajowniczek visited St. Maximilian Kolbe Catholic Church of West Chester, Pennsylvania and also in Houston, Texas, where he told his translator Chaplain Thaddeus Horbowy that "so long as he ... has breath in his lungs, he would consider it his duty to tell people about the heroic act of love by Maximilian Kolbe." Gajowniczek died in the city of Brzeg on 13 March 1995 at the age of 93. He was buried at Niepokalanów, a religious community founded by Maximilian Kolbe, 53 years after Kolbe saved his life. He was survived by his second wife, Janina.
the restructuring of websites that causes changes in URLs (e.g. domain.net/pine_tree might be moved to domain.net/tree/pine) relocation of formerly free content to behind a paywall a change in server architecture that results in code such as PHP functioning differently dynamic page content such as search results that changes by design deletion of the target page and/or its content the presence of user-specific information (such as a login name) within the link deliberate blocking by content filters or firewalls the expiration of a domain name registration
Sources: en.wikipedia.org
=== Batch reactor === Batch reactors are reactors in which the reactants are put in the reactor at time 0 and react until the reaction is stopped. Consequently, the space time is the same as the average residence time in a batch reactor.
[Adenosyl−O−PO2−O−PO2−O−PO3]4− + ROH → [Adenosyl−O−PO2−O−PO3H]2− + [RO−P−O3]2− This equation can be written in several ways that are nearly equivalent that describe the behaviors of various protonated states of ATP, ADP, and the phosphorylated product. As is clear from the equation, a phosphate group per se is not transferred, but a phosphoryl group (PO3-). Phosphoryl is an electrophile. This process and its inverse, dephosphorylation, are common in biology. Protein phosphorylation often activates (or deactivates) many enzymes.
== History == Erythritol was discovered in 1848 by the Scottish chemist John Stenhouse and first isolated in 1852. Starting from 1945, American chemists applied newly-developed techniques of chromatography to sugarcane juice and blackstrap molasses, finding in 1950 that erythritol was present in molasses fermented by yeast. It was first approved and marketed as a sweetener in Japan in 1990, and in the US in 1997. In February 1997, Cerestar Holding Co., Mitsubishi Chemical Co., and Nikken Chemicals Co. submitted a formal generally recognized as safe (GRAS) affirmation petition with the US FDA. However, in April 1997 the FDA replaced the GRAS affirmation petition process with the current GRAS notification process, a notice was first filed by Cerestar in April 2001, and the FDA responded with "no questions" in September 2001.
== Function == The pituitary glycoprotein hormone family includes follicle-stimulating hormone, luteinizing hormone, chorionic gonadotropin, and thyroid-stimulating hormone. All of these glycoproteins consist of an identical alpha subunit and a hormone-specific beta subunit. This gene encodes the beta subunit of follicle-stimulating hormone. In conjunction with luteinizing hormone, follicle-stimulating hormone induces egg and sperm production. The FSHB gene in human DNA encodes the follicle-stimulating hormone subunit beta protein (FSH-B), or Follitropin Beta. More specifically, the FSHB gene encodes for the beta subunit of follicle-stimulating hormone (FSH). Therefore, proper transcription of FSHB allows for the proper production of FSH. FSH is a peptide hormone the pituitary gland produces that is involved with the reproductive system. FSH promotes follicular oocyte (egg) production, growth, and maturation and helps control a female's menstrual cycle. Additionally, FSH is involved in the male reproductive system by stimulating spermatogenesis (maturation of sperm cells) and initiating puberty. Studies show that variations in the FSHB gene can contribute to the likelihood of a woman becoming pregnant with fraternal, or dizygotic, twins. This is because certain heritable variations of FSHB contribute to increased production of FSH from the pituitary gland, raising the levels of FSH found in a woman's blood. It is also shown that women with these FSHB variants had their first menstrual cycle, children, and menopause at an earlier age than women without the variant.
For just as a man has a body that is no different in principle from that of an animal, so also his psychology has a whole series of lower storeys in which the spectres from humanity's past epochs still dwell, then the animal souls from the age of Pithecanthropus and the hominids, then the "psyche" of the cold-blooded saurian. Jung's notion of different evolutionary layers in the human mind has been compared with the work of neuroscientist Jaak Panksepp, particularly as outlined in his book The Archaeology of Mind: Neuroevolutionary Origins of Human Emotions. Of these affinities it has been suggested that 'Jung and Panksepp have, independently it seems, developed similar metaphors of an archeologically layered psyche in which jewels and treasures are discoverable in the deepest phylogenetically ancient regions of the brain – for Jung they are archetypal structures for Panksepp cross-species homologies.' Significantly, in a 2017 article entitled "The Affective Core of the Self: A Neuro-Archetypical Perspective on the Foundations of Human (and Animal) Subjectivity", when noting Jung's belief that archetypes may be related to evolutionarily ancient subcortical brain systems, Panksepp and colleagues wrote that "such assertions by Jung were not only quite farsighted, but they actually open ways to connect his theory of the psyche with the most advanced scientific theories and discoveries of our day."
Sources: en.wikipedia.org
=== Eastern Docks === Dover's Eastern Docks were used for ship breaking beginning during the First World War, when the Admiralty began dismantling ships there. The Stanlee Shipbreaking and Salvage Co. Ltd. took over the ship breaking operation commercially in 1920. Many of the ships broken up were naval vessels from the First World War. The company also handled machinery and general scrap, including the dismantling of the Dover Promenade Pier. The yard began to shrink after World War II and was closed in 1964 to make way for port redevelopment and a car ferry terminal. From 1930 until 1950 an aerial ropeway carried coal from Tilmanstone colliery, 7½ miles to the north. It emerged halfway up the Langdon cliffs directly above the Eastern harbour arm, through two portals which have been bricked up but can still be seen from the ferry port. Coal was deposited in bunkers at the outer end of the Eastern harbour arm. The ropeway had 600 1-ton buckets that departed at intervals of 21 seconds and travelled at 4½ miles per hour. The system could thus transport 120 tons of coal per hour.
Winter count - Several Native American groups in the Great Plains have used winter counts as pictorial calendars for record-keeping. Writing system – many indigenous American cultures, such as the Olmec, Maya, Aztec, Zapotec, and Toltec, developed Mesoamerican writing systems. Other native peoples to the north—mainly Algonquians—had organized pictographing, a common precursor of writing. (See Massachusett writing systems, Ojibwe writing systems.)
=== Future developments === When insulin pump technology is combined with a continuous blood glucose monitoring system, the technology seems promising for real time control of the blood sugar level. Currently there are no mature algorithms to automatically control the insulin delivery based on feedback of the blood glucose level. When the loop is closed, the system may function as an artificial pancreas. Insulin pumps are being used for infusing pramlintide (brand name Symlin, or synthetic amylin) with insulin for improved postprandial glycemic control compared to insulin alone. Dual hormone insulin pumps that infuse either insulin or glucagon. In event of hypoglycemia, the glucagon could be triggered to increase the blood glucose. This would be particularly valuable in a closed loop system under the control of a glucose sensor. The Artificial Pancreas, currently in clinical trials for FDA approval, is a recently developed device designed with this technology in mind. Ultrafast insulins are insulins that are absorbed more quickly than the currently available Humalog, Novolog, and Apidra which have a peak at about 60 minutes could be administered. Faster insulin uptake would theoretically coordinate with meals better, and allow faster recovery from hyperglycemia if the insulin infusion is suspended. Biodel is developing an ultrafast insulin
The body of a teleost is denser than water, so fish must compensate for the difference, or they will sink. A defining feature of Actinopteri (Chondrostei, Holostei and teleosts) is the swim bladder. Originally present in the last common ancestor of the teleosts, it has since been lost independently at least 30–32 times in at least 79 of 425 families of teleosts where the swim bladder is absent in one or more species. This absence is often the case in fast-swimming fishes such as the tuna and mackerel. The swim bladder helps fish adjusting their buoyancy through manipulation of gases, which allows them to stay at the current water depth, or ascend or descend without having to waste energy in swimming. In the more primitive groups like some minnows, the swim bladder is open (physostomous) to the esophagus. In fish where the swim bladder is closed (physoclistous), the gas content is controlled through the rete mirabilis, a network of blood vessels serving as a countercurrent gas exchanger between the swim bladder and the blood.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.